Press Release
10 February 2022
GenScript Biotech Corporation (Stock Code: 1548.HK), the world's leading life science research tools and services provider, today announced the opening of more than 30,000-square-feet facility for highly automated protein and gene preparation services. The state-of-the-art site marks a significant expansion of the company's advanced protein and gene platforms, and is designed to provide high quality, fast-turnaround on products required for new vaccines and therapeutics development and innovations in life sciences. Supported by the Singapore’s Economic Development Board (EDB), the new production site will support the Asia Pacific region and complements the current production sites in the United States and China.
The opening ceremony was held on a virtual setting inaugurated by Minister of State for Trade and Industry, and Culture, Community and Youth, Mr Alvin Tan and accompanied by Senior Vice President and Head, Healthcare, Singapore Economic Development Board (EDB), Ms Goh Wan Yee. During the ceremony, GenScript and A*STAR Diagnostics Development Hub signed on a memorandum of understanding (MoU) to explore the possibility of collaborations for the purposes of building manufacturing capabilities in Singapore.
The new manufacturing facility occupies over 30,000 square feet space at Solaris@Kallang building. The cutting edge facility in Singapore features a high throughput platform and proprietary technology of GenScript’s protein production to provide higher yield with a shorter turnaround time. Together with an experienced scientific and commercial team, GenScript is committed to provide tailored and top notch service to the region. The capacity of the new facility could also be expanded to strengthen other business units to support cell and gene therapy and vaccine development in the region.
